Kancera: Focusing on science to defeat cancer




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Kancera: Focusing on science to defeat cancer
Released on: September 25, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Kancera is a collaboration between industry and academic scientists in the Karolinska Innovation Park in Sweden with a number of drug development projects.
  • Summary
  • Transcript
  • Participants
  • Company
Kancera is a collaboration between industry and academic scientists in the Karolinska Innovation Park in Sweden with a number of drug development projects. They have an exciting lead program where they have identified a foetal growth factor that goes dominant in adults but becomes active again in cancer as the driving force of apoptosis. By inhibiting this onco-foetal target they believe they may defeat these cancers.
Kancera is a collaboration between industry and academic scientists in the Karolinska Innovation Park in Sweden with a number of drug development projects. They have an exciting lead program where they have identified a foetal growth factor that goes dominant in adults but becomes active again in cancer as the driving force of apoptosis. By inhibiting this onco-foetal target they believe they may defeat these cancers.
Thomas Olin was born in 1958 and is the CEO. Ph.D. in physiology and M.Sc. in biology, chemistry and geosciences. Olin has more than 20 years' experience of both scientific and business management from biotechnology and pharmaceutical companies. He was part of the management group that led the hiving off of Biovitrum from Pharmacia and was later part of the research and business development management at Biovitrum. Olin was responsible for the hiving off of iNovacia from Biovitrum in 2006 and has been CEO at iNovacia since 2006. He also has extensive experience of the licensing of pharmaceutical development projects.
Kancera unites industrial and clinical expertise. The goal is to develop a new generation of cancer drugs to combat those properties that currently cause tumors to recur, often in a more malignant and resistant form. Kancera has four pharmaceutical projects in its existing product development portfolio, in disease areas of leukaemia and solid tumors. The development of the new drug types is being carried out as a close collaboration between clinical and industrial expertise. This creates the opportunity to make the risky development of new methods of treatment more reliable. Kancera was founded in the spring of 2010. On February 25, 2011, the share was linked into the NASDAQ OMX First North.